Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1486 - The expression of interleukin 17 receptor A is associated with poor prognosis in patients with colorectal cancer and its knockdown inhibits tumor growth and modulates tumor-infiltrating immune cells in mice tumor


09 Sep 2017


Poster display session


Translational Research;  Colon and Rectal Cancer


Chih-Yung Yang


Annals of Oncology (2017) 28 (suppl_5): v158-v208. 10.1093/annonc/mdx393


C. Yang1, C. Lin2, J. Jiang3

Author affiliations

  • 1 Department Of Education And Research, Taipei City Hospital, 106 - Taipei/TW
  • 2 Institute Of Microbiology And Immunology, National Yang-Ming University, 112 - Taipei/TW
  • 3 Department Of Surgery, Taipei Veterans General Hospital, 112 - Taipei/TW


Abstract 1486


Interleukin 17 receptor type A (IL17RA) is a potent mediator in the pathogenesis and progression of colorectal cancer. Our previous study has shown that IL17A is a potential therapeutic target in modulating tumorigenesis, and metastasis, and serves as a prognostic marker in colorectal cancer (CRC), but the role of IL17RA in colonic tumorigenesis is still not clear. This study aims to evaluate the potential role and function of IL17RA in CRC.


IL17RA expression was determined in colorectal cancer tissues and adjacent normal tissues of CRC patients by using quantitative RT-PCR and immunohistochemistry. To investigate the functional significance of IL17RA expression, and clinical significance of IL17RA expression in CRC patients, disease-free survival was analyzed in patients with CRC. The IL17RA knockdown stable clones were used for in vitro migration/invasion assay and were subcutaneously implanted in mice to measure tumor growth.


A higher IL17RA mRNA level in tumor tissue of CRC patients than adjacent normal tissues (p = 0.0016) was found and it was significantly correlated with recurrence (p = 0.008) and poor disease-free survival (P 


IL-17RA participates in mediating tumor growth and angiogenesis of CRC and plays a crucial role in the progression of CRC. It could serve as prognostic marker of CRC patients and could potentially be used as a therapeutic target in clinical application.

Clinical trial identification

Legal entity responsible for the study

Chih-Yung Yang




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.